{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:07Z","timestamp":1707524347507},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,27]]},"DOI":"10.7759\/cureus.16658","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T12:55:11Z","timestamp":1627390511000},"source":"Crossref","is-referenced-by-count":0,"title":["An Uncharacteristic Presentation of Evans Syndrome Following Treatment With Dupilumab"],"prefix":"10.7759","author":[{"given":"Megan","family":"Rutherford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anam","family":"Mazharuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieanna","family":"Camarena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S176144","article-title":"Evans syndrome: clinical perspectives, biological insights and treatment modalities","volume":"9","author":"Jaime-P\u00e9rez JC","year":"2018","unstructured":"Jaime-P\u00e9rez JC, Aguilar-Calder\u00f3n PE, Salazar-Cavazos L, G\u00f3mez-Almaguer D. Evans syndrome: clinical perspectives, biological insights and treatment modalities. J Blood Med. 2018, 9:171-84. 10.2147\/JBM.S176144","journal-title":"J Blood Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-215368","article-title":"The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases","volume":"114","author":"Michel M","year":"2009","unstructured":"Michel M, Chanet V, Dechartres A, et al.. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009, 114:3167-72. 10.1182\/blood-2009-04-215368","journal-title":"Blood"},{"key":"ref3","article-title":"Roth Spots","author":"Ruddy SM","year":"2020","unstructured":"Ruddy SM, Bergstrom R, Tivakaran VS. Roth Spots. StatPearls Publishing, Treasure Island; 2020."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-229636","article-title":"Premacular haemorrhage in a child with Evans syndrome","volume":"12","author":"Verma G","year":"2019","unstructured":"Verma G, Nayak L, Banerjee A, Nayak B. Premacular haemorrhage in a child with Evans syndrome. BMJ Case Rep. 2019, 12:bcr-2019-229636. 10.1136\/bcr-2019-229636","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2012.01.060","article-title":"A case of Evans' syndrome following influenza vaccine","volume":"44","author":"Shlamovitz GZ","year":"2013","unstructured":"Shlamovitz GZ, Johar S. A case of Evans' syndrome following influenza vaccine. J Emerg Med. 2013, 44:e149-51. 10.1016\/j.jemermed.2012.01.060","journal-title":"J Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.6.1051","article-title":"Evans's syndrome triggered by recombinant hepatitis B vaccine","volume":"15","author":"Mart\u00ednez E","year":"1992","unstructured":"Mart\u00ednez E, Domingo P. Evans's syndrome triggered by recombinant hepatitis B vaccine. Clin Infect Dis. 1992, 15:1051. 10.1093\/clind\/15.6.1051","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0214-9","article-title":"Immunotherapy-associated autoimmune hemolytic anemia","volume":"5","author":"Khan U","year":"2017","unstructured":"Khan U, Ali F, Khurram MS, Zaka A, Hadid T. Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer. 2017, 5:15. 10.1186\/s40425-017-0214-9","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517729766","article-title":"Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab","volume":"24","author":"Meunier B","year":"2018","unstructured":"Meunier B, Rico A, Seguier J, et al.. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Mult Scler. 2018, 24:811-3. 10.1177\/1352458517729766","journal-title":"Mult Scler"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512442262","article-title":"Severe haematological complications during treatment with natalizumab","volume":"18","author":"Midaglia L","year":"2012","unstructured":"Midaglia L, Rodriguez Ruiz M, Mu\u00f1oz-Garc\u00eda D. Severe haematological complications during treatment with natalizumab. Mult Scler. 2012, 18:1644-6. 10.1177\/1352458512442262","journal-title":"Mult Scler"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.021","article-title":"Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis","volume":"58","author":"Kwan JM","year":"2008","unstructured":"Kwan JM, Reese AM, Trafeli JP. Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. J Am Acad Dermatol. 2008, 58:1053-5. 10.1016\/j.jaad.2008.01.021","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.3433","article-title":"Autoimmune hemolytic anemia during adalimumab treatment for plaque psoriasis","volume":"54","author":"Harada Y","year":"2015","unstructured":"Harada Y, Yamamoto H, Sato M, Kodaira M, Kono T. Autoimmune hemolytic anemia during adalimumab treatment for plaque psoriasis. Intern Med. 2015, 54:1103-4. 10.2169\/internalmedicine.54.3433","journal-title":"Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000055110","article-title":"Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder","volume":"44","author":"Jourdan E","year":"2003","unstructured":"Jourdan E, Topart D, Richard B, Jourdan J, Sotto A. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk Lymphoma. 2003, 44:889-90. 10.1080\/1042819021000055110","journal-title":"Leuk Lymphoma"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10733","article-title":"Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients","volume":"92","author":"Elimelakh M","year":"2007","unstructured":"Elimelakh M, Dayton V, Park KS, et al.. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica. 2007, 92:1029-36. 10.3324\/haematol.10733","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro M","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al.. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018, 378:2486-96. 10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1871463","article-title":"Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study [PREPRINT]","author":"Beck LA","year":"2021","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, et al.. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study [PREPRINT]. J Dermatolog Treat. 2021, 1-9. 10.1080\/09546634.2020.1871463","journal-title":"J Dermatolog Treat"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14740\/jmc3336","article-title":"Dupilumab-associated acquired hemophilia a in an elderly male with severe eczema","volume":"10","author":"Dayag D","year":"2019","unstructured":"Dayag D, Shaikh N, Lee P, Granet K. Dupilumab-associated acquired hemophilia a in an elderly male with severe eczema. J Med Cases. 2019, 10:206-8. 10.14740\/jmc3336","journal-title":"J Med Cases"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb H","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020, 50:5-14. 10.1111\/cea.13491","journal-title":"Clin Exp Allergy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00458-6","article-title":"Facial erythema after the treatment of dupilumab in SLE patient","volume":"16","author":"Jang DH","year":"2020","unstructured":"Jang DH, Lee JI, Bae JY, Jung HJ, Park MY, Ahn J. Facial erythema after the treatment of dupilumab in SLE patient. Allergy Asthma Clin Immunol. 2020, 16:60. 10.1186\/s13223-020-00458-6","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.12.1887","article-title":"Th1\/Th2 cells in inflammatory disease states: therapeutic implications","volume":"4","author":"Moss RB","year":"2004","unstructured":"Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W, Encinas J, Carlo DJ. Th1\/Th2 cells in inflammatory disease states: therapeutic implications. Expert Opin Biol Ther. 2004, 4:1887-96. 10.1517\/14712598.4.12.1887","journal-title":"Expert Opin Biol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/60329-an-uncharacteristic-presentation-of-evans-syndrome-following-treatment-with-dupilumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:52Z","timestamp":1707506872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/60329-an-uncharacteristic-presentation-of-evans-syndrome-following-treatment-with-dupilumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.16658","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,27]]}}}